TP73 Antibody

What are the main isoforms of TP73 and which antibody types are available to detect them?

TP73 exists in multiple isoforms that result from alternative splicing and promoter usage. The major groups include:

• TAp73 isoforms: Contain the transactivation domain and have tumor-suppressive properties

• ΔNp73 isoforms: Lack the N-terminal transactivation domain and generally have oncogenic functions

• C-terminal variants: Include p73α, p73β, p73γ, p73ε, and others that differ in their C-terminal regions

Antibodies for these isoforms include:

• PAN-p73 antibodies: Recognize all p73 isoforms but may cross-react with other p53 family members

• TAp73-specific antibodies: Target the N-terminal transactivation domain (epitopes like YFDLP at amino acids 28-32)

• ΔNp73-specific antibodies: Target the unique N-terminus of ΔNp73 (epitopes like YVGDP at amino acids 3-8)

• p73α-specific antibodies: Target the C-terminal region of p73α (e.g., last 18 amino acids CKARKQPIKEEFTEAEIH)

• p73γ/ε antibodies: Target unique C-terminal peptides like PRDAQQPWPRSASQRRDE

What applications are TP73 antibodies typically validated for?

TP73 antibodies have been validated for multiple applications:

• Western Blotting (WB): Most commonly used, dilutions typically around 1:1,000

• Immunohistochemistry (IHC): For paraffin-embedded tissues, dilutions of 1:50-1:200

• Immunocytochemistry (ICC)/Immunofluorescence (IF): Dilutions of 1:50-1:200

• Flow Cytometry (FC): For analysis of cellular expression levels

• Immunoprecipitation (IP): For protein interaction studies

• ELISA: For quantitative detection

Validation should include positive controls (cells transfected with the specific p73 isoform) and negative controls (cells lacking p73 expression) .

How should I validate the specificity of a TP73 antibody before use in critical experiments?

Thorough validation of TP73 antibodies is crucial due to potential cross-reactivity with other p53 family members:

• Expression system testing: Test the antibody on cells transfected with specific p73 isoforms versus non-transfected controls to confirm specificity

• Cross-reactivity assessment: Test against p53 and p63 isoforms to ensure there is no unintended binding to these related proteins

• Epitope mapping: Consider using phage display epitope mapping to identify the exact binding site, which helps understand potential cross-reactions

• Multiple detection methods: Confirm results using at least two different techniques (e.g., WB and IHC)

• Isoform panel testing: Test against a panel of all major p73 isoforms (TAp73α, TAp73β, ΔNp73α, etc.) to determine precise isoform specificity

The study by Nemajerova et al. showed that antibody validation against cells transfected with all p73 isoforms, p63 isoforms, and p53 provided comprehensive specificity data .

What are optimal protocols for detecting low-abundance TP73 isoforms?

Detecting low-abundance TP73 isoforms like p73γ requires specialized approaches:

• Enhanced detection systems:

  • For Western blots: Use highly sensitive ECL substrates and longer exposure times

  • For IHC/IF: Consider tyramide signal amplification systems

• Enrichment strategies:

  • Immunoprecipitation before Western blotting

  • Use of phosphatase inhibitors to prevent degradation of phosphorylated forms

• Custom antibody development:

  • For specific isoforms like p73γ/ε, generate antibodies against unique C-terminal peptides

  • Validate using knockout or knockdown models

• RNA-based complementary methods:

  • RT-PCR with isoform-specific primers to confirm protein detection results

  • Example primers for p73α/β/γ/ε: forward 5'-CAG CAG CAG CAG CTC CTA CA-3' and reverse 5'-TAC TGC TCG GGG ATC TTC AG-3'

How can I distinguish between TAp73 and ΔNp73 isoforms in tissue samples?

Distinguishing between these functionally opposite isoforms is critical:

• Isoform-specific antibodies:

  • Use TAp73-specific antibodies targeting the transactivation domain

  • Use ΔNp73-specific antibodies targeting the unique N-terminal sequence

• Sequential immunostaining protocol:

  • First round: ΔNp73-specific antibody with one fluorophore

  • Antibody stripping/blocking step

  • Second round: TAp73-specific antibody with different fluorophore

  • Nuclear counterstain (DAPI)

• Controls for validation:

  • Positive control: Cell lines with known expression of specific isoforms

  • Negative control: Use blocking peptides specific to each isoform

• Interpretation guideline:

  • Nuclear staining is expected for both isoforms

  • Relative intensity differences may indicate biological significance

  • Consider ratio of TAp73:ΔNp73 rather than absolute levels

How can multiplex staining be optimized to detect TP73 alongside other p53 family members?

Multiplex detection of p53 family members requires careful planning:

• Antibody selection criteria:

  • Choose antibodies from different host species (e.g., mouse anti-p53, rabbit anti-p73, goat anti-p63)

  • Verify non-overlapping epitopes to prevent steric hindrance

• Sequential staining protocol:

  • Apply primary antibodies sequentially rather than simultaneously

  • Use Tyramide Signal Amplification (TSA) for signal enhancement

  • Include antibody stripping/blocking between rounds

• Demonstrated technique:

  • A successful triple immunofluorescent approach used:

    • Mouse monoclonal p73-1.1 (recognizing p73α) with Alexa Fluor 488

    • Mouse monoclonal PAN-p63 6.1 with Alexa Fluor 647

    • Rabbit polyclonal p53 (CM-1) with Alexa Fluor 555

  • Nuclear counterstaining with NucBlue Stain allows cell identification

• Data analysis considerations:

  • Quantify co-expression patterns using scatter plots (similar to the TP63 versus TP73 RNA-seq expression analysis)

  • Calculate Spearman's rank correlation coefficient (rs) between expression levels

What approaches can detect post-translational modifications of TP73 proteins?

TP73 undergoes several post-translational modifications that affect its function:

• Modification-specific antibodies:

  • Phospho-specific antibodies for various sites

  • Acetylation-specific antibodies (e.g., p73 Acetyl Lys327)

  • Ubiquitination/sumoylation detection requires specialized approaches

• Enrichment protocol:

  • Immunoprecipitate total p73 first

  • Then probe with modification-specific antibodies

  • Include phosphatase/deacetylase inhibitors in all buffers

• Functional validation:

  • Correlate modifications with activity using reporter assays

  • Compare DNA damage-induced versus basal conditions to detect stress-responsive modifications

• Known modifications to monitor:

  • Ubiquitination: Affects protein stability

  • Sumoylation: Alters protein interactions and localization

  • Phosphorylation: Impacts transcriptional activity

How can TP73 antibodies be used to study the relationship between isoform expression and cancer progression?

Investigating TP73 isoforms in cancer requires systematic approaches:

• Tissue microarray analysis protocol:

  • Use isoform-specific antibodies on cancer tissue microarrays

  • Score nuclear vs. cytoplasmic staining intensity

  • Correlate with clinical parameters and survival data

• Cell line model studies:

  • Compare isoform expression across cancer progression models

  • Example: Adult T-cell leukemia/lymphoma (ATL) patients show TP73 structural variants affecting exons 2-3

  • Create isogenic lines with specific isoform expression

• Functional implications:

  • TAp73 isoforms: Generally tumor-suppressive, promoting apoptosis

  • ΔNp73 isoforms: Oncogenic, acting as dominant-negative inhibitors of TAp73, TAp63, and p53

  • The p73γ isoform specifically promotes tumorigenesis through the Leptin pathway

• Clinical correlation:

  • In ATL patients, TP73 structural variants with deletion of exons 2–3 were associated with competitive advantage and increased proliferation

  • Expression in Huntington's disease striatal neurons suggests non-cancer roles

What are common causes of non-specific bands when using TP73 antibodies in Western blots?

Non-specific bands are a frequent issue with TP73 antibodies:

• Common sources of non-specificity:

  • Cross-reactivity with other p53 family members (especially p63)

  • Detection of alternatively spliced isoforms not previously characterized

  • Post-translational modifications affecting migration

  • Degradation products

• Troubleshooting approach:

  • Include positive controls (transfected cells expressing specific isoform)

  • Run side-by-side with cells expressing p53 and p63 to identify cross-reactivity

  • Use knockout or knockdown samples as negative controls

  • Consider the expected molecular weight (canonical human protein: 636 amino acids, 69.6 kDa)

• Solution table:

  Problem	Possible Cause	Solution
  Multiple bands	Alternative isoforms	Use isoform-specific antibodies
  Band at wrong size	Cross-reactivity	Validate with transfected controls
  Weak signal	Low expression	Immunoprecipitate before Western blotting
  Smeared bands	Protein degradation	Add protease inhibitors, reduce sample processing time

• Special consideration:

  • The commonly used mouse monoclonal antibody 38C674.2 (IMG-313 A) to ΔNp73 binds to a non-specific band in Western blotting

How should discrepancies between TP73 mRNA and protein detection be addressed?

Discrepancies between mRNA and protein levels are common with TP73:

• Potential causes:

  • Post-transcriptional regulation of TP73

  • Variations in protein stability between isoforms

  • Limited sensitivity of antibodies compared to PCR

  • Differential expression of specific isoforms not detected by pan-antibodies

• Complementary approaches:

  • Perform isoform-specific RT-PCR alongside protein detection

  • Use primer sets that can distinguish between splice variants

  • Example RT-PCR primers for human p73α/β/γ/ε: 5'- CAG CAG CAG CAG CTC CTA CA-3' (forward) and 5'-TAC TGC TCG GGG ATC TTC AG-3' (reverse)

  • For mouse p73α/β: 5'- GCG AGG CCG GGA GAA CTT TGA G-3' (forward) and 5'- TGG CTC TGC TTC AGG TCC TGT AGG C-3' (reverse)

• Reconciliation strategies:

  • Assess protein stability (cycloheximide chase assay)

  • Examine post-translational modifications

  • Consider the intragenic super-enhancer regulation of TP73 expression

  • Check for structural variants that may affect antibody binding but not mRNA detection

What controls are essential when interpreting TP73 antibody staining in tissue sections?

Proper controls are critical for accurate interpretation of TP73 staining:

• Essential controls to include:

  • Positive tissue control (tissue known to express TP73)

  • Negative tissue control (tissue not expressing TP73)

  • Antibody absorption/blocking peptide control

  • Isotype control (matched concentration of non-specific IgG)

• Isoform validation approach:

  • Use serial sections with different isoform-specific antibodies

  • Include tissues from knockout models when available

  • For human tissues, consider including known expression patterns (e.g., skin showing differentiation-dependent expression)

• Interpretation guidelines:

  • Normal TP73 is primarily nuclear with some cytoplasmic localization

  • Striatal neurons in Huntington's disease patients can serve as positive controls

  • Exclusively cytoplasmic staining should be carefully validated as potential non-specificity

  • Co-staining with p63 can help interpret skin and epithelial tissues where both are expressed

The study by Nemajerova et al. demonstrated that appropriately validated antibodies show exclusively nuclear staining for p73, while some commercial antibodies showed widespread cytoplasmic staining that was non-specific .

How can TP73 antibodies be applied in studying structural variants in cancer?

Recent discoveries highlight the importance of TP73 structural variants in cancer:

• Detection strategy:

  • Combine genomic analysis with antibody-based protein detection

  • Use PCR primers flanking common deletion boundaries

  • Example: ATL patients show deletions of exons 2-3

• Clinical significance assessment:

  • Correlate structural variants with clinical outcomes

  • In ATL patients, TP73 SVs with exon 2-3 deletion conferred competitive advantage

  • Evaluate correlation with super-enhancer formation

• Experimental approach:

  • Generate isogenic cell lines with CRISPR-induced structural variants

  • Compare protein detection patterns using different domain-specific antibodies

  • Correlate with functional effects on proliferation and apoptosis

• Emerging detection methods:

  • Consider using antibodies against fusion junctions created by structural variants

  • Combine with RNA-seq data to validate protein expression from variant transcripts

This approach has revealed clinically relevant TP73 structural variants in adult T-cell leukemia/lymphoma that were associated with disease progression .

What are the best practices for using TP73 antibodies in multiplex tissue analysis platforms?

As multiplex technologies advance, optimizing TP73 detection becomes crucial:

• Platform considerations:

  • Mass cytometry (CyTOF): Metal-conjugated TP73 antibodies

  • Multiplex IHC: TSA-based sequential staining

  • Digital spatial profiling: Compatible antibodies for spatial context

• Antibody selection criteria:

  • High specificity validated across multiple methods

  • Compatible with multiplex fixation protocols

  • Defined epitope to minimize steric hindrance with other antibodies

• Technical optimization:

  • Titrate antibodies specifically for multiplex platforms

  • Determine optimal antigen retrieval compatible with other targets

  • Establish careful blocking protocols to prevent cross-reactivity

• Analysis approach:

  • Correlate TP73 isoform expression with spatial features

  • Assess co-expression with other p53 family members

  • Integrate with functional markers (proliferation, apoptosis)